Human leukocyte antigen class I gene mutations in cervical cancer

Journal of the National Cancer Institute

Volumn 91, Issue 19, 1999, Pages 1669-1677

  Koopman, Louise A ^a   Van Der Slik, Arno R ^b   Giphart, Marius J ^b   Fleuren, Gert Jan ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; LEUKOCYTE ANTIGEN;

ALLELISM; ANTIGEN EXPRESSION; ARTICLE; DNA DETERMINATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 0033530298     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.19.1669     Document Type: Article

References (47)

1. Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, Poggi A, et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol Rev 1997;155:105-17.
2. Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 1997;24:293-312.
3. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18: 89-95.
4. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-7.
5. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
6. Cordon Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991;51:6372-80.
7. Cromme FV, van Bommel PF, Walboomers JM, Gallee MP, Stern PL, Kenemans P, et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer 1994;69:1176-81.
8. Hilders CG, Morgado Munoz IM, Nooyen Y, Fleuren GJ. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol 1995;57:366-75.
9. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996;62:33-41.
10. Duggan-Keen MF, Keating PJ, Stevens FR, Sinnott P, Snijders PJ, Walboomers JM, et al. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet 1996;23:275-84.
11. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
12. Browning M, Petronzeili F, Bicknell D, Krausa P, Rowan A, Tonks S, et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996;47:364-71.
13. Koopman LA, Mulder A, Corver WE, Anholts JD, Giphart MJ, Claas FH, et al. HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens 1998;51:623-36.
14. Bicknell DC, Rowan A, Bodmer WF. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci USA 1994;91:4751-6.
15. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S, β2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998;101:2720-9.
16. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumors on. Immunol Today 1997;18:292-9.
17. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
18. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996;47:372-81.
19. Browning MJ, Krausa P, Rowan A, Hill AB, Bicknell DC, Bodmer JG, et al. Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for anti-tumor immunity and immunotherapy. J Immunother 1993;14:163-8.
20. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res 1998;58:2149-57.
21. Zemmour J, Little AM, Schendel DJ, Parham P. The HLA-A.B "negative" mutant cell line ClR expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992;148: 1941-8.
22. Imreh MP, Zhang QJ, de Campos-Lima PO, Imreh S, Krausa P, Browning M, et al. Mechanisms of allele-selective down-regulation of HLA class 1 in Burkitt's lymphoma. Int J Cancer 1995;62:90-6.
23. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci U S A 1993;90:2842-5.
24. Foung SK, Taidi B, Ness D, Grumet FC. A monoclonal antibody against HLA-A11 and A24. Hum Immunol 1986;15:316-9.
25. Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994;57:805-13.
26. Tonks S, Marsh SG, Bunce M, Moses JH, Kravsa P, Sadler AM, et al. HLA class I DNA typing study. In: Charron D, Fauchet R, editors. HLA. Genetic diversity of HLA. Functional and medical implications. Proceedings of the 12th International Histocompatibility Workshop and Conference. Vol. 1. Paris (France): EDK; 1997. p. 199-215.
27. Kohler S, Wehling J, Blasczyk R. Structural diversity of the HLA-A regulatory complex. In: Charron D, Fauchet R, editors. HLA. Genetic diversity of HLA. Functional and medical implications. Proceedings of the 12th International Histocompatibility Workshop and Conference. Vol. 2. Paris (France): EDK; 1997. p. 285-7.
28. Laforet M, Froelich N, Parissiadis A, Bausinger H, Pfeiffer B, Tongio MM. An intronic mutation responsible for a low level of expression of an HLA-A*24 allele. Tissue Antigens 1997;50:340-6.
29. Verduyn W, Doxiadis II, Anholts J, Drabbels JJ, Naipal A, D'Amaro J, et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol 1993;37:59-67.
30. Cawkwell L, Li D, Lewis FA, Martin I, Dixon MF, Quirke P. Microsatellite instability in colorectal cancer: improved assessment using fluorescent polymerase chain reaction. Gustroenterology 1995;109:465-71.
31. Hanifi Moghaddam P, de Knijf P, Roep BO, Van der Auwera B, Naipal A, Gorus F. et al. Genetic structure of IDDMI: two separate regions in the major histocompatibility complex contribute to susceptibility or protection. Belgian Diabetes Registry. Diabetes 1998;47:263-9.
32. Kersemaekers AM, Kenter GG, Hermans J, Fleuren GJ, van de Vijver MJ. Allelic loss and prognosis in carcinoma of the uterine cervix. Int J Cancer 1998;79:411-7.
33. Brandie D, Brasseur F, Weynants P, Boon T, Van den Eynde BJ. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996;183:2501-8.
34. de Nooij-van Dalen AG, van Buuren-van Seggelen VH, Lohman PH, Giphart-Gassler M. Chromosome loss with concomitant duplication and recombination both contribute most to loss of heterozygosity in vitro. Genes Chromosomes Cancer 1998;21:30-8.
35. Magor KE, Taylor EJ, Shen SY, Martinez-Naves E, Valiante NM, Wells RS, et al. Natural inactivation of a common HLA allele (A*2402) has occurred on at least three separate occasions. J Immunol 1997;158: 5242-50.
36. Mine H, Ishakawa Y, Hojo M, Imashuku S, Tuji T, Saji H, et al. An HLA-B null allele (B*1526N) with a stop codon in exon 3 generated by a point mutation. Tissue Antigens 1997;50:351-4.
37. Hilders CG, Houhiers JG, Krul EJ, Fleuren GJ. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994;101:5-12.
38. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walboomers JM, Hunter RD, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-I expression. Br J Cancer 1995;72:405-11.
39. Arguello JR, Little AM, Pay AL, Gallardo D, Rojas I, Marsh SG, et al. Mutation detection and typing of polymorphic loci through double-strand conformation analysis. Nat Genet 1998;18:192-4.
40. Wang Z, Margulies L, Hicklin DJ, Femme S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 1996;47:382-90.
41. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression [letter]. Lancet 1998;351:187-8.
42. Rader JS, Gerhard DS, O'Sullivan MJ, Li Y, Li L, Liapis H, et al. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer 1998;22:57-65.
43. Kotsch K, Wehling J, Kohler S, Blasczyk R. Sequencing of HLA class I genes based on the conserved diversity of the noncoding regions: sequencing-based typing of the HLA-A gene. Tissue Antigens 1997;50:178-91.
44. Cereb N, Kong Y, Lee S, Maye P, Yang SY. Nucleotide sequences of MHC class I introns 1, 2, and 3 in humans and intron 2 in nonhuman primates [published erratum appears in Tissue Antigens 1996;48:235-6]. Tissue Antigens 1996;47:498-511.
45. Johnston-Dow L, Bengtson A, Scheltinga S, Rozemuller E, Pera C, Chen Y, et al. DNA sequencing based typing of HLA-A. In: Charron D, Fauchet R, editors. HLA. Genetic diversity of HLA. Functional and medical implications. Proceedings of the 12th International Histocompatibility Workshop and Conference. Vol. I. Paris (France): EDK; 1997. p. 250-4.
46. Foissac A, Crouau-Roy B, Faure S, Thomsen M, Cambon-Thomsen A. Microsatellites in the HLA region: an overview. Tissue Antigens 1997:49(3 Pt 1):197-214.
47. Devilee P, van Schothorst EM, Bardoel AF, Bonsing B, Kuipers-Dijkshoorn N, James MR. et al. Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL. Genes Chromosomes Cancer 1994;11: 71-8.